BioSkryb has introduced a brand new era of amplification for single-cell whole genome. The advantages of BioSkryb ResolveDNA™ technology comprise the capability to manage the amplicon size during the amplification process. This enables the integration of barcode identifiers into each sample template, resulting in unmatched reproducibility and the precise detection of DNA lesions. Our comprehensive workflow solution is particularly valuable in cancer research, as it facilitates the identification of individual resistant mutant cells (MRD) in heterogeneous cancers like leukemia. The leadership team at BioSkryb possesses extensive scientific and management experience spanning decades.